The Plant-Derived Chalcone 2,2',5'-Trihydroxychalcone Provides Neuroprotection against Toll-Like Receptor 4 Triggered Inflammation in Microglia by Jiwrajka, M et al.
Research Article
The Plant-Derived Chalcone 2,2󸀠,5󸀠-Trihydroxychalcone
Provides Neuroprotection against Toll-Like Receptor 4
Triggered Inflammation in Microglia
Manasi Jiwrajka,1 Alexandra Phillips,2 Matt Butler,2
Miriam Rossi,3 and Jennifer M. Pocock2
1Mayne Medical School, 288 Herston Road, Brisbane, QLD 4006, Australia
2Department of Neuroinflammation, University College London Institute of Neurology, 1 Wakefield Street, London WC1N 1PK, UK
3Department of Chemistry, Vassar College, 124 Raymond Avenue, Poughkeepsie, NY 12604-0484, USA
Correspondence should be addressed to Jennifer M. Pocock; j.pocock@ucl.ac.uk
Received 20 July 2015; Accepted 30 September 2015
Academic Editor: Felipe Dal Pizzol
Copyright © 2016 Manasi Jiwrajka et al.This is an open access article distributed under the Creative CommonsAttribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Chalcones are plant metabolites with potential for therapeutic exploitation as antioxidant, anti-inflammatory, and antiproliferative
agents. Here we explored the neuroprotective effects of 2,2󸀠,5󸀠-trihydroxychalcone (225THC), a potent antioxidant with radical-
scavenging properties. 225THCwas found to be a potent inhibitor of apoptosis in stimulated primary rat neuronal cultures.Thiswas
likelymediated by an anti-inflammatory effect onmicroglial cells since 225THC inhibited LPS-stimulatedTNF-𝛼 and IL-6 secretion
from primary rat microglia andmodulated the cytokine/chemokine profile of BV2microglial cells. Additionally, 225THC inhibited
LPS-evoked inducible nitric oxide synthase expression but did not influence endogenous superoxide generation. Microglial flow
cytometric analyses indicated the 225THC treatment induced a shift fromanM1-like phenotype to amore downregulatedmicroglial
profile. Taken together these data suggest that the chalcone 2,2󸀠,5󸀠-trihydroxychalcone canmodulate neuroinflammatory activation
in brain-derived microglia and holds promise as a therapeutic in neuroinflammatory conditions.
1. Introduction
Plants produce secondarymetabolites that protect them from
toxins and insects. Some of these plant metabolites, such as
chalcones, have significant antioxidant, anti-inflammatory,
and antiproliferative properties in a range of cell types [1–
7]. Chalcones are similar to other known antioxidants such
as resveratrol, curcumin, and ubiquinone and are the natural
precursors of flavonoids and isoflavonoids in higher plants
[4, 8–10]. In plants, chalcones protect against UV expo-
sure, pathogens, and insects, and their antioxidant and anti-
inflammatory properties make them of increasing interest in
the treatment of human conditions such as cancer, inflamma-
tion, tuberculosis, and malaria [2, 7, 11].
Stress and injury to cells can cause the production of
free radicals and the release of cytokines. In the brain, such
substances are produced by the activation of microglia, the
brain’s resident phagocytes, leading to neurotoxicity [12–14].
During ageing, neurodegeneration, ischaemia, brain injury,
or other neuropathologies, there is enhanced production of
free radicals and cytokines, increased apoptosis, and reduced
expression of synaptic or growth proteins [15–18].
In the brain, the chalcone isoliquiritigenin has anxiolytic
effects [19] whilst two chalconoids from the desert plant
Pulicaria incisa inhibited the production of reactive oxygen
species (ROS) by astrocytes and prevented their oxidant-
induced cell death [20]. One plant-derived chalcone, 2,2󸀠,5󸀠-
trihydroxychalcone (225THC), demonstrated strong antioxi-
dant and radical-scavenging properties in L-6 myoblasts and
THP-1 humanmonocytes [21]. However, the neuroprotective
effects of this particular chalcone on cells of the CNS are
unknown and the subject of the present study.
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2. Materials and Methods
2.1. Cell Culture
2.1.1. BV2 Microglia. The BV2 mouse microglial cell line was
a kind gift from Dr. Claudie Hooper, Institute of Psychiatry,
Kings College London, and was originally obtained from the
Department of Life Sciences, National Cheng Kung Univer-
sity, Taiwan. The cells were cultured in RPMI-1640 medium
(Gibco, Life Technologies) plus 5% foetal bovine serum
(FBS) and 50U/mLpenicillin and 50𝜇g/mL streptomycin (all
Invitrogen, http://www.invitrogen.com/) at 37∘C, at 5% CO
2
,
and at a density of 2× 104 per 13mmglass coverslips in 24-well
plates or 1 × 105 per 6-well plate forWestern blotting or FACS
analyses and rested overnight at 37∘C plus 5% CO
2
. Before
use, cell medium was replaced with RPMI plus 1% FBS.
2.1.2. Primary Cultures of Microglia and Cerebellar Granule
Cell Neurons. Sprague Dawley rat pups (postnatal day 5)
were bred and reared in-house from stock animals (Charles
River UK, Kent, UK) and were sacrificed in accordance
with Schedule 1 of the Animals Scientific Procedures Act
(1986) UK, for the culture of primary microglia and cere-
bellar neurons. Microglia were cultured as described pre-
viously [22]. Briefly, cells were plated on 13mm glass cov-
erslips in 24 well plates at 0.5 × 105 cells/well and main-
tained in culture medium consisting of MEM (Invitrogen,
http://www.invitrogen.com/), supplemented with 10% FBS,
20mM KCl, 20mM D-glucose, 2mM D-glucose, 25mM
NaHCO
4
, 50U/mL penicillin, 50 𝜇g/mL streptomycin, and
6 𝜇g/mL ampicillin. The microglia were maintained at 37∘C,
6% CO
2
and used 1 day after plating. Where possible
experiments were carried out using primary microglia but
where assays required higher cell numbers, BV2 microglia
were used. We have previously compared responses of BV2
microglia and primarymicroglia and have found not obvious
differences in responses. Cerebellar granule cells (CGCs)
were cultured as described previously [22]. The cells were
plated on 13mm glass coverslips in 24 well plates at a density
of 8 × 105/coverslip and maintained in culture medium
(MEM plus 10% FBS, 20mM KCl, 30mM D-glucose, 2mM
L-glutamine, 25mM NaHCO
4
, 50U/mL penicillin, 50𝜇M
streptomycin, and 6 𝜇g/mL ampicillin) that was later supple-
mented with 20𝜇M cytosine furanoarabinoside (Ara-C) to
control glial proliferation. The cells were maintained at 37∘C,
6% CO
2
and used after 8 days in vitro (8 DIV).
2.2. Chalcone Treatment. The chalcone 2,2󸀠,5󸀠-trihydroxy-
chalcone (225THC) was purchased from Indofine Chemical
Co. (Hillsborough, NJ, USA, at 97% purity) and was applied
to microglia and neurons to test for any inherent toxicity.
225THC was added at (final concentrations) 1𝜇M, 5 𝜇M,
10 𝜇M, 25 𝜇M, 50𝜇M, 100 𝜇M, or 500 𝜇M in 100% sterile
DMSO (Sigma D2650; hybri-MAX) as well as a solvent
control of 100% DMSO and incubated for 24 h. Live/dead
assays were carried out using Hoechst 33342 for total cell
number and propidium iodide (PI) for dead cells as pre-
viously described [22]. Cells were visualised and images
captured with a Zeiss Axioskop 2 fluorescence microscope
(Oberkochen, Germany) and images were captured using
Zeiss Axiovision Imaging System 4.8 software. The number
of live/dead cells was counted manually, or using Image
J software. At least 5 fields per coverslip, 3 coverslips per
225THC concentration from 3 separate cell platings were
analysed.
2.3. 225THC Treatment of Surveillant and Inflammatory
Microglia. The effects of 225THC on microglial activation
were tested by treating primary microglia or BV2 microglia
with 225THC (1𝜇M, 5 𝜇M, 10 𝜇M, 50 𝜇M, 100 𝜇M, and
500𝜇M) with or without 2𝜇g/mL of the Toll-like receptor 4
(TLR4) agonist, lipopolysaccharide (LPS), for 24–48 h. This
concentration of LPS was used as this produces maximal
iNOS expression as determined in previous experiments
and published papers from our laboratory [14, 23]. The
cells were subsequently analysed by live/dead assay, Western
blot, and cell supernatants analysed for cytokine secre-
tion as described. To test for protective effects of 225THC
against neuroinflammation-driven neurotoxicity, CGCs were
directly treated with 225THC (5 𝜇M, 50 𝜇M, and 500 𝜇M)
and then either 2𝜇g/mL LPS or 10 ng/mL IFN-𝛾 to activate
resident microglia in the cultures. Following 24 h, CGC
cultures were analysed by Hoechst 33342 staining to assess
nuclear morphology as described previously [22].
2.4. Western Blot of Inducible Nitric Oxide Synthase Expres-
sion. Cells were treated for Western blotting using standard
techniques followed by blot visualisationwith ECL. Beta- (𝛽-)
actin was used as a loading control in all gels and protein
bands analysed following densitometry with Image J soft-
ware. Primary antibodies used were anti-iNOS, 1 : 2500,
overnight followed by 1 : 5000 HRP conjugated goat anti-
rabbit, for 1 h, and anti-𝛽 actin 1 : 10000 overnight, fol-
lowed by HRP conjugated goat anti-mouse, 1 : 20,0000 for
1 h. Goat anti-rabbit peroxidase secondary antibodywas from
Sigma (Poole, UK), donkey anti-goat peroxidase secondary
antibody was from GeneTex (Insight Biotech, Wembley
UK), goat anti-arginase-1 was from Santa Cruz Biotech
(http://www.scbt.com/), and rabbit anti-inducible nitric
oxide synthase (iNOS)was fromBDBiosciences (http://www
.bdbiosciences.com/).
2.5. Dihydroethidium Fluorescence Imaging of Superoxide
Generation. The superoxide sensitive fluorescent dye dihy-
droethidium (dHEth) was used to assess microglial super-
oxide generation and its regulation by the chalcone. Dihy-
droethidium is oxidised to 2-hydroxyethidium (2-OH-E+)
upon exposure to superoxide specifically, correlating with a
shift in fluorescence from blue to red which is detectable
by fluorescence microscopy [24] and we have used this
previously to assess superoxide generation in microglia [22].
BV2 microglia were treated with 225THC, LPS, or 10 nM
phorbol 12-myristate 13-acetate (PMA) (the latter as a positive
control for the generation of superoxide by NADPH activity
[22, 25]) for 24 h and then incubated with 5𝜇M dHEth
for 40min to identify superoxide-producing microglia as
described previously [22] plus 0.6 𝜇g/mL Hoechst 33342 for
40min was used to counterstain all nuclei for total cell
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number. Microglia were imaged by fluorescence microscopy
as above, and superoxide-positive microglia, as indicated by
red nuclei, were counted and expressed as a percentage of
total cell number. To ensure that the red fluorescence was due
to superoxide production, experiments were carried out by
incubation of the cells with 10 𝜇M apocynin [22].
2.6. ELISA of Secreted Cytokines by Microglia. TNF-𝛼 or
IL-1𝛽 concentrations in primary rat microglia cell culture
supernatants were quantified using Quantikine Rat TNF-𝛼
or IL-1𝛽 Immunoassay kit according to the manufacturer’s
instructions (R&D Systems, Abingdon UK). Cytokine con-
centrations in cell supernatants were determined against a
standard curve of TNF-𝛼 or IL-1𝛽. In addition, a range
of inflammatory mediators were analysed in BV2 cell cul-
ture supernatants with an Inflammatory ELISA strip assay
according to the manufacturer’s instructions (Signosis Inc.,
Caltag MedSystems Ltd., Buckingham, UK). In this case, all
values were presented as a percentage of control values. For
each condition, the cytokine content in supernatants was
analysed from three coverslips of microglia in three inde-
pendent cell platings with each sample assayed in duplicate.
All other chemicals and reagents were from Sigma (Poole,
UK).
2.7. Flow Cytometric Analysis of Microglial Inflammatory
Markers. BV2 cells were treated with 1, 5, or 10 𝜇M of
225THC for 2 hours prior to the addition of 2 𝜇g/mL LPS
for a further 48 hours. Cells were harvested by washing in
Dulbecco’s phosphate buffered saline (PBS, without Ca2+ and
Mg2+) for 20 minutes at 37∘C and then resuspended in cold
PBS containing 0.5% BSA/0.05% NaN
3
to metabolically fix
the cells. Cells were stained with anti-mouse CD11b-FITC,
CD40-FITC, CD54-FITC, and CD68-FITC, or appropriate
FITC-conjugated isotype control antibodies (Miltenyi Biotec,
UK) as per the manufacturer’s instructions and cell sur-
face staining was assessed by flow cytometry (FACSCalibur
running CellQuest Pro; Becton Dickinson, UK) and anal-
ysed using Flowing software v2.5.1. Data are presented as
average fold change in mean fluorescence intensity (MFI)
versus untreated cells ± SEM from 4 independent experi-
ments.
2.8. Statistical Analysis. Statistical analyses were performed
using one-way ANOVA with Tukey post hoc analysis, where
comparisons were made between treatments and control
untreated cells, and also between treatment groups as indi-
cated. Where stated, Student’s 𝑡-test was used and all data
were from 3 separate experiments, ∗𝑝 < 0.05, ∗∗𝑝 < 0.01,
and ∗∗∗𝑝 < 0.005 compared with controls or as indicated in
figures.Where imagingwas performed, aminimumof 3 fields
of viewwere analysed from 3 coverslips per condition. Images
of fluorescent fields of cells orWestern blots are representative
of analysed data from3 independent experiments.Thedensit-
ometry forWesternswas performedusing Image J,measuring
the optical density (OD) of each band and normalising to the
𝛽-actin obtained for that particular sample. For the statistical
analysis of these data, each treatment was compared with
control untreated cells by ANOVA analysis, and appropriate
comparisons were also made between treatment groups ±
inhibitors using Student’s 𝑡-test.
3. Results and Discussion
3.1. Effects of 225THC in Primary Rat Cerebellar Granule
Cell Neuronal Cultures. We initially investigated whether the
225THCwas directly toxic to neurons by incubating primary
rat cerebellar granule cell (CGC) neuronal culture neurons
with concentrations of 5–500𝜇M 225THC for 24 h. This
range of concentrations was assessed as previous studies
using similar compounds have identified activity within this
range [20, 26, 27]. Microscopic live/dead analyses revealed
no significant toxicity in these cultures with DMSO solvent
control, or with 5, 50, or 500𝜇M 225THC (Figure 1(a))
when compared with untreated cells. We next investigated
the potential neuroprotective properties of 225THC in these
cultures (which we have shown previously contain 2–5%
microglia) [28, 29]. A range of 225THC concentrations were
preincubated with CGCs for 1 hour, followed by stimulation
with 2𝜇g/mL LPS or 10 ng/mL IFN-𝛾 to induce an inflam-
matory phenotype within the CGC cultures. After 24 h, the
CGCs were imaged with Hoechst 33342 to visualise apop-
totic nuclei within the cultures. LPS or IFN-𝛾 significantly
increased the percentage of apoptotic cells in the neuronal
cultures above basal (Figure 1(b)) whilst pretreatment with
225THC at 50 or 500 𝜇Msignificantly reduced the percentage
of apoptotic cells in cultures treated with LPS or IFN-𝛾. Since
LPS and IFN-𝛾 are potent activators of microglia, with no
known effects on cerebellar neurons and since incubation
with chalcone directly to these cultures, in the absence of
inflammation, did not enhance basal levels of neuronal sur-
vival, it is likely that suppression of the neuroinflammatory
and neurotoxic effects seen here are due to suppression
of microglial responses. Thus we determined how these
effects might be mediated. One proposed mechanism for
the neurotoxicity observed is that activated microglia release
proinflammatory cytokines that cause cytotoxicity to the
neurons [15, 30, 31].
3.2. 225THC Inhibits Proinflammatory Cytokine Secretion by
LPS-Stimulated Primary Rat Microglial Cells. As a prelimi-
nary assessment, we again investigated the potential cellular
toxicity of 225THC when added to primary rat microglial
cultures. We observed that, in three separate experiments, a
specific concentration of 50𝜇M 225THC appeared to induce
significant cell loss fromcoverslips in both nonstimulated and
LPS-stimulated cells, whilst concentrations above and below
this did not (Figure 2(a)). This was most likely due to loss
of contact rather than toxicity as there was no increase in PI
staining. DMSO controls did not affect cell numbers (data not
shown).
We next assessed cytokine secretion inmicroglial cell cul-
ture supernatants under basal (nonstimulating conditions)
and following LPS stimulation (2𝜇g/mL) in the presence
of 50 or 500𝜇M 225THC (Figure 2(b)). The basal secretion
of TNF-𝛼, IL-6, and IL-10 was not significantly modulated
by 5 𝜇M or 500𝜇M 225THC whilst LPS-evoked TNF-𝛼 and
IL-6 secretion, but not IL-10, was significantly inhibited by
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Figure 1: 225THC is nontoxic and neuroprotective in stimulated primary rat neuronal cultures (cerebellar granule cell neurons; CGCs).
Effects of 225THC on primary rat CGC neurons. (a) Toxicity assay of 225THC on primary rat CGC neurons. Data from three separate
experiments represent the mean number of live neurons (as assessed by live/dead assay) present per field of view following incubation for
24 h with different concentrations of 225THC (0, 5, 50, and 500 𝜇M) for 24 h. DMSO is the solvent control; basal is CGCs with nothing added.
Statistical analysis was performed by ANOVA with Bonferroni post hoc analysis and revealed no toxicity at the concentrations tested when
all concentrations were compared with basal. The DMSO solvent control was also not toxic. (b) Direct treatment of CGC cultures for 24 h
with 225THC (0, 5, 50, and 500𝜇M) and 2 𝜇g/mL LPS or 10 ng/mL IFN-𝛾 to activate resident microglia in the cultures. The percentage of
apoptotic cells following Hoechst 33342 visualisation of nuclear condensation is shown for each treatment. Statistical analysis was performed
by a two-way ANOVA with Bonferroni post hoc analysis; ∗ ∗ ∗ indicates 𝑝 < 0.001; ns, not significant when compared as indicated or with
the appropriate basal control.
5 𝜇M or 500𝜇M 225THC (Figures 2(bi), 2(bii), and 2(biii),
resp.).
3.3. 225THC Modulates Inflammatory Cytokine and Chemo-
kine Responses in Murine BV2Microglial Cells. To investigate
the microglial aspects further, we used the BV2 mouse
microglial cell line which is a well validated substitute for
primary microglia [32]. Further examination of a lower
range of 225THC concentrations (1𝜇M, 5 𝜇M, and 10 𝜇M)
following a 48 h LPS stimulation revealed selective inhi-
bition of LPS-induced TNF-𝛼, in line with our findings
in primary microglia (Figure 3(a)). In addition, the basal
secretion of monocyte chemoattractant protein-1 (MCP-1)
was also significantly inhibited (Figure 3(b)). We did not
observemodulation of basal or LPS-evoked secretion of IFN-
R, IL-1𝛼, IL-1𝛽, (data not shown) or of RANTES (Figure 3(c))
or MIP (Figure 3(d)). These data suggest that 225THC has
an effect on the secretion of inflammatory cytokines such
as TNF-𝛼, IL-6, and MCP-1, and the reduction of these
cytokines may aid neuroprotection. Interestingly, in line with
our findings, Herencia et al. [26] report that the chalcone
used in their study inhibited TNF-𝛼 mouse air pouch tissue
levels from leukocytes stimulated by zymosan, whilst Bano et
al. [33] reported suppression of LPS-evoked TNF-𝛼 secretion
from a mouse macrophage line with a synthetic chalcone. In
addition, we found 225THC inhibited the secretion of two
other cytokines, IL-6 and MCP-1. IL-6 has well recognised
roles in neuroinflammation and promotes microgliosis [34]
whilst MCP-1 (also known as CCL-2) acts as a chemoattrac-
tant to recruit monocytes and macrophages into the brain
[35]. Interestingly, recent work suggests different chalcones
may selectively inhibit the secretion of different groups of
cytokines and inflammatory mediators [27]. We did not see
significant modulation by 225THC of RANTES, MIP, or IL-
10. Other chalcones have been shown to promote the produc-
tion of neurotrophic factors such as GDNF from astrocytes
[20] and this is worth future exploration for microglia.
3.4. Modulation of iNOS Expression and ROS Generation
by 225THC. The expression of iNOS was assessed in BV2
microglia under basal conditions and following LPS stimu-
lation (2 𝜇g/mL) for 48 h in the presence of 225THC (1𝜇M,
5 𝜇M, or 10 𝜇M). No obvious effects were observed on the
expression of iNOS in nonstimulated microglia; that is,
225THC did not induce expression of iNOS (Figure 4(a)).
However LPS-evoked stimulation of iNOS expression was
significantly inhibited by 225THC at concentrations above
5 𝜇M(Figures 4(a) and 4(b)).We next investigatedmicroglial
superoxide generation using microscopic fluorescence imag-
ing (Figure 4(c)). No obvious effects of the 225THC were
observed on the basal cell numbers expressing superoxide-
positive cell nuclei and whilst the number of superoxide-
positive cells was increased following LPS stimulation this
was not significantly regulated by 225THC concentrations
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Figure 2: 225THC is nontoxic and inhibits inflammatory cytokine responses in stimulated primary rat microglial cultures. Effects of 225THC
on primary rat microglial cells. (a) Toxicity assay of 225THC on primary cultured rat microglia. Data shown from three separate experiments
represent the mean number of live primary microglia (as assessed by live/dead assay) present per field of view following incubation for
24 h with different concentrations of 225THC (0, 1, 5, 10, 50, and 100 𝜇M) for 24 h with or without coactivation of the microglia with LPS
(2𝜇g/mL). (b) ELISA assessment of secreted cytokines in LPS (2 𝜇g/mL) activated primary rat microglia cultures treated with 225THC at the
concentrations indicated. Statistical analysis was performed by a two-way ANOVA with Bonferroni post hoc analysis; ∗ indicates 𝑝 < 0.05,
∗∗
𝑝 < 0.01; when compared with basla or as indicated.
from 1 to 100 𝜇M(Figure 4(c)) or at 500𝜇M(data not shown).
The positive control of NADPH oxidase activation, PMA
(10 ng/mL), induced a significant increase in superoxide-
positive cells, in line with previous findings [22].
The inhibition of iNOS expression in microglia is in
agreement with findings for another chalcone, 4-dimethyl-
amino-3󸀠,4󸀠-dimethoxychalcone, on mouse macrophages
stimulated with zymosan [22]. This chalcone inhibited iNOS
expression with a similar concentration (∼10 𝜇M) to the chal-
cone used in the present study. Herencia et al. [26] proposed
that the effect on iNOS expression was via upstreammodula-
tion of NADPH oxidase-mediated intracellular signalling.
Since we did not detect modulation of microglial superoxide
generation by 225THC, it seems unlikely that this particular
chalcone possesses this mechanism of action. Other chal-
cones have also been reported to modulate nitric oxide pro-
duction, or iNOS expression following LPS stimulation of a
mouse macrophage cell line [36], the BV2 microglial cell line
[27], and a rat microglial cell line [37] within similar com-
pound concentration ranges of 1–50 𝜇M.The exact signalling
pathways inhibited by different chalcones may be diverse,
as some studies suggest modulation of nuclear factor-𝜅B,
MAPK, or c-Jun pathways and others suggest STAT1 path-
ways may be involved [26, 37].
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Figure 3: 225THC modulates inflammatory cytokine and chemokine responses in murine BV2 microglial cells. 225THC-modulation of
cytokine/chemokine secretion by the BV2 microglial cell line. ELISA assessment of cytokine ((a) TNF-𝛼) and chemokine ((b) MCP-1; (c)
RANTES; (d) MIP) secretion by BV2 microglial cells following stimulation with LPS (2 𝜇g/mL) for 24 h in the presence of 225THC at the
concentrations indicated. Statistical analysis was performed by a two-way ANOVA with Bonferroni post hoc analysis; ∗ indicates 𝑝 < 0.05,
∗∗
𝑝 < 0.01; ns, not significant when compared with basal or as indicated.
3.5. Modulation ofMicroglial Inflammatory Phenotype. Upon
LPS stimulation,microglia adopt an inflammatory phenotype
which is characterised by enhanced cell surface expression of
key adhesion (CD11b, CD54), and costimulatory molecules
(CD40). We investigated the effects of 225THC treatment
on BV2 cell surface expression of CD11b, CD40, CD54, and
CD68 in basal and LPS-treated BV2 microglia (Figure 5).
Flow cytometric analysis (FACs) of marker mean fluores-
cence intensity (MFI) revealed no significant changes in basal
CD40, CD54, CD68, or CD11b expression levels following
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Figure 4: 225THC inhibits the LPS-induced expression of iNOS, but not NADPH-driven superoxide production, in BV2 microglia.
Modulation of BV2 iNOS expression, but not superoxide production, by 225THC. Representative Western blots of iNOS expression and 𝛽-
actin as a loading control (a) and densitometry (b) of three separate blots for BV2microglia exposed to 225THC at the stated concentrations ±
LPS (2𝜇g/mL) for 24 h. Statistical analysis was performed by a two-way ANOVAwith Bonferroni post hoc analysis; ∗ indicates 𝑝 < 0.05when
compared with basal or as indicated. (c) Superoxide generation in BV2 microglia measured by dihydroethidium fluorescence following 24 h
exposure to 225THC at the concentrations indicated ± LPS (2𝜇g/mL). The phorbol, PMA, was used as a positive activator of superoxide
generation. (d) Representative fields of BV2 microglia generating intracellular superoxide following 24 h exposure to 225THC +/− LPS.
Statistical analysis was performed by a two-way ANOVA with Bonferroni post hoc analysis; ∗ indicates 𝑝 < 0.05; ∗∗ indicates 𝑝 < 0.01
when compared with basal or as indicated.
225THC treatment for 48 h (data not shown). However, fol-
lowing stimulation with 2 𝜇g/mL LPS, CD40 (Figure 5(bii)),
CD54 (Figure 5(cii)), and CD68 (Figure 5(dii)) were signif-
icantly upregulated and these changes in expression were
abrogated in the presence of 5 or 10 𝜇M 225THC. CD40
appeared to be the most potently regulatedmarker, with both
5 and 10 𝜇M 225THC completely inhibiting LPS-induced
upregulation (Figure 5(bii)) while the treatment had more
moderate effects on CD54 and CD68 marker expression. As
in the basal state, 225THC had no effect on CD11b expression
by LPS-stimulated microglia (Figure 5(aii)).
Overall, these data suggest that 225THC targets the
signalling pathways downstream of LPS binding and abro-
gates the expression of genes such as TNF-𝛼, iNOS, and
CD40. Since these are all reported NF-𝜅B driven genes,
future work could investigate this further to identify the
exact pathways modified by 225THC. Abrogating this gene
expression produced a less neurotoxic microglial phenotype
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(d)
Figure 5: 225THC treatmentmodulates inflammatory cell surfacemarker expression in LPS-treated BV2microglia. Flow cytometric analysis
of 225THC-treated BV2 microglia following LPS stimulation. (a) Representative histogram plots of BV2 cell surface CD11b, CD40, CD54,
and CD68 expression following 2 𝜇g/mL LPS-treatment for 48 hours (unfilled histograms), versus isotype control (black-filled histograms),
and in the presence of 10 𝜇M 225THC (grey-filled histograms). (b) Summary data showing fold changes in CD11b, CD40, CD54, or CD68
expression by mean fluorescence intensity (MFI) from 4 independent experiments. Data are mean values ± SEM where ∗ indicates 𝑝 < 0.05
by Student’s 𝑡-test.
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which is likely to be beneficial for a number of neurodegen-
erative diseases in which aberrant microglial inflammatory
reactivity is implicated. Future work could pinpoint further
the microglial phenotype favoured by 225THC exposure and
explore the genotype of the microglia.
Abbreviations
ANOVA: Analysis of variance
DPPH: 2,2-Diphenyl-1-picrylhydrazyl
dHEth: Dihydroethidium
CGCs: Cerebellar granule neurons
DIV: Days in vitro
DAPI: 4󸀠,6-Diamidino-2-phenylindole
DMSO: Dimethylsulphoxide
ECL: Electrochemiluminescence
ELISA: Enzyme-linked immunosorbent assay
GABAA: 𝛾-Aminobutyric acid
IFN-𝛾: Interferon-𝛾
IL-1𝛽: Interleukin-1𝛽
IL-6: Interleukin-6
IL-10: Interleukin-10
iNOS: Inducible nitric oxide synthase
LPS: Lipopolysaccharide
MCP-1: CCL2/monocyte chemoattractant
protein-1
MEM: Modified Eagle’s medium
MIP: Macrophage inhibitory protein
MCP-1: Monocyte chemoattractant protein-1
NGS: Normal goat serum
PBS: Phosphate buffered saline
PFA: Paraformaldehyde
2-OH-E+: 2-Hydroxyethidium
RANTES: CCL5/regulation on activation normal T
cell expressed and secreted
ROS: Reactive oxygen species
TNF-𝛼: Tumour necrosis factor-𝛼.
Conflict of Interests
All authors declare no conflict of interests.
Acknowledgments
Manasi Jiwrajka would like to thank Dr. Kathleen Susman for
her guidance. This research was supported by the University
of Queensland Advantage Grant, Howard Hughes Medical
Foundation Grant 52006322 to Vassar College, the Sherman
Fairchild Foundation, and Vassar College and by general
funds to the Pocock lab.
References
[1] S. Ducki, R. Forrest, J. A. Hadfield et al., “Potent antimitotic and
cell growth inhibitory properties of substituted chalcones,” Bio-
organic and Medicinal Chemistry Letters, vol. 8, no. 9, pp. 1051–
1056, 1998.
[2] M. L. F. Ferreyra, S. P. Rius, and P. Casati, “Flavonoids: biosyn-
thesis, biological functions, and biotechnological applications,”
Frontiers in Plant Science, vol. 3, article 222, 15 pages, 2012.
[3] G. E.-D. A. A. Abuo-Rahma, M. Abdel-Aziz, M. A. E. Mourad,
and H. H. Farag, “Synthesis, anti-inflammatory activity and
ulcerogenic liability of novel nitric oxide donating/chalcone
hybrids,” Bioorganic and Medicinal Chemistry, vol. 20, no. 1, pp.
195–206, 2012.
[4] N. K. Sahu, S. S. Balbhadra, J. Choudhary, and D. V. Kohli,
“Exploring pharmacological significance of chalcone scaffold,”
Current Medicinal Chemistry, vol. 19, no. 2, pp. 209–225, 2012.
[5] H. Wei, X. Zhang, G. Wu et al., “Chalcone derivatives from the
fern Cyclosorus parasiticus and their anti-proliferative activity,”
Food and Chemical Toxicology, vol. 60, pp. 147–152, 2013.
[6] C. W. Mai, M. Yaeghoobi, N. Abd-Rahman, Y. B. Kang, and
M. R. Pichika, “Chalcones with electron-withdrawing and ele-
ctron-donating substituents: anticancer activity against TRAIL
resistant cancer cells, structure-activity relationship analysis
and regulation of apoptotic proteins,” European Journal of
Medicinal Chemistry, vol. 77, pp. 378–387, 2014.
[7] Z. Nowakowska, “A review of anti-infective and anti-inflam-
matory chalcones,” European Journal of Medicinal Chemistry,
vol. 42, no. 2, pp. 125–137, 2007.
[8] Y.-M. Lin, Y. Zhou, M. T. Flavin, L.-M. Zhou, W. Nie, and F.-C.
Chen, “Chalcones and flavonoids as anti-tuberculosis agents,”
Bioorganic and Medicinal Chemistry, vol. 10, no. 8, pp. 2795–
2802, 2002.
[9] J.Mojzis, L. Varinska, G.Mojzisova, I. Kostova, and L.Mirossay,
“Anti-angiogenic effects of flavonoids and chalcones,” Pharma-
cological Research, vol. 57, no. 4, pp. 259–265, 2008.
[10] F. Dal Piaz, A. Braca, M. A. Belisario, and N. De Tommasi,
“Thioredoxin systemmodulation by plant and fungal secondary
metabolites,” Current Medicinal Chemistry, vol. 17, no. 5, pp.
479–494, 2010.
[11] N. Yadav, S. K. Dixit, A. Bhattacharya et al., “Antimalarial activ-
ity of newly synthesized chalcone derivatives in vitro,” Chem-
ical Biology and Drug Design, vol. 80, no. 2, pp. 340–347, 2012.
[12] F. V. DeFeudis, “Novel therapy for Alzheimer’s disease,” Neuro-
biology of Aging, vol. 10, no. 5, pp. 467–468, 1989.
[13] Y. Nomura and Y. Kitamura, “Inducible nitric oxide synthase
in glial cells,” Neuroscience Research, vol. 18, no. 2, pp. 103–107,
1993.
[14] P. J. Kingham, M. L. Cuzner, and J. M. Pocock, “Apoptotic path-
ways mobilized in microglia and neurones as a consequence
of chromogranin A-induced microglial activation,” Journal of
Neurochemistry, vol. 73, no. 2, pp. 538–547, 1999.
[15] S. Singh, S. Swarnkar, P. Goswami, and C. Nath, “Astrocytes and
microglia: responses to neuropathological conditions,” Inter-
national Journal of Neuroscience, vol. 121, no. 11, pp. 589–597,
2011.
[16] Y. Y. Deng, J. Lu, E.-A. Ling, and C. Kaur, “Role of microglia in
the process of inflammation in the hypoxic developing brain,”
Frontiers in Bioscience (Scholar Edition), vol. 3, no. 3, pp. 884–
900, 2011.
[17] M. Dumont and M. F. Beal, “Neuroprotective strategies involv-
ing ROS in Alzheimer disease,” Free Radical Biology and
Medicine, vol. 51, no. 5, pp. 1014–1026, 2011.
[18] A.D. Kraft andG. JeanHarry, “Features ofmicroglia and neuro-
inflammation relevant to environmental exposure and neuro-
toxicity,” International Journal of Environmental Research and
Public Health, vol. 8, no. 7, pp. 2980–3018, 2011.
[19] S. Cho, S. Kim, Z. Jin et al., “Isoliquiritigenin, a chalcone com-
pound, is a positive allosteric modulator of GABA A recep-
tors and shows hypnotic effects,” Biochemical and Biophysical
Research Communications, vol. 413, no. 4, pp. 637–642, 2011.
10 Oxidative Medicine and Cellular Longevity
[20] A. Elmann, A. Telerman, H. Erlank et al., “Protective and anti-
oxidant effects of a chalconoid from Pulicaria incisa on brain
astrocytes,”OxidativeMedicine andCellular Longevity, vol. 2013,
Article ID 694398, 10 pages, 2013.
[21] M. Rossi, F. Caruso, E. J. Crespi et al., “Probing antioxidant
activity of 2󸀠-hydroxychalcones: crystal and molecular struc-
tures, in vitro antiproliferative studies and in vivo effects on
glucose regulation,” Biochimie, vol. 95, no. 10, pp. 1954–1963,
2013.
[22] E. L.Mead, A.Mosley, S. Eaton, L. Dobson, S. J. Heales, and J.M.
Pocock, “Microglial neurotransmitter receptors trigger super-
oxide production in microglia; consequences for microglial-
neuronal interactions,” Journal of Neurochemistry, vol. 121, no.
2, pp. 287–301, 2012.
[23] C. M. Davenport, I. G. Sevastou, C. Hooper, and J. M. Pocock,
“Inhibiting p53 pathways in microglia attenuates microglial-
evoked neurotoxicity following exposure to Alzheimer pep-
tides,” Journal of Neurochemistry, vol. 112, no. 2, pp. 552–563,
2010.
[24] N. C. Garbett, N. B. Hammond, and D. E. Graves, “Influence of
the amino substituents in the interaction of ethidium bromide
with DNA,” Biophysical Journal, vol. 87, no. 6, pp. 3974–3981,
2004.
[25] A. Karlsson, J. B. Nixon, and L. C. McPhail, “Phorbol myristate
acetate induces neutrophilNADPH-oxidase activity by two sep-
arate signal transduction pathways; dependent or independent
of phosphatidylinositol 3-kinase,” Journal of Leukocyte Biology,
vol. 67, no. 3, pp. 396–404, 2000.
[26] F. Herencia, M. L. Ferrandiz, A. Ubeda et al., “4-Dimethyl-
amino-3󸀠,4󸀠-dimethoxychalcone down-regulates iNOS expres-
sion and exerts anti-inflammatory effects,” Free Radical Biology
& Medicine, vol. 30, no. 1, pp. 43–50, 2001.
[27] N. Mateeva, M. Gangapuram, E. Mazzio, S. Eyunni, K. F.
Soliman, and K. K. Redda, “Biological evaluation of synthetic
chalcone and flavone derivatives as anti-inflammatory agents,”
Medicinal Chemistry Research, vol. 24, no. 4, pp. 1672–1680,
2015.
[28] S. C. Morgan, D. L. Taylor, and J. M. Pocock, “Microglia release
activators of neuronal proliferation mediated by activation
of mitogen-activated protein kinase, phosphatidylinositol-3-
kinase/Akt and delta-Notch signalling cascades,” Journal of
Neurochemistry, vol. 90, no. 1, pp. 89–101, 2004.
[29] J. Jebelli, T. Piers, and J. Pocock, “Selective depletion of micro-
glia from cerebellar granule cell cultures using L-leucinemethyl
ester,”The Journal of Visualized Experiments, no. 101, Article ID
e52983, 2015.
[30] R. Von Bernhardi, J. E. Tichauer, and J. Eugenı´n, “Aging-
dependent changes of microglial cells and their relevance for
neurodegenerative disorders,” Journal of Neurochemistry, vol.
112, no. 5, pp. 1099–1114, 2010.
[31] C. Schwab and P. L. McGeer, “Inflammatory aspects of
Alzheimer disease and other neurodegenerative disorders,”
Journal of Alzheimer’s Disease, vol. 13, no. 4, pp. 359–369, 2008.
[32] A. Henn, S. Lund, M. Hedtja¨rn, A. Schrattenholz, P. Po¨rzgen,
and M. Leist, “The suitability of BV2 cells as alternative model
system for primary microglia cultures or for animal experi-
ments examining brain inflammation,” Altex, vol. 26, no. 2, pp.
83–94, 2009.
[33] S. Bano, K. Javed, S. Ahmad et al., “Synthesis of some novel chal-
cones, flavanones and flavones and evaluation of their anti-
inflammatory activity,” European Journal of Medicinal Chem-
istry, vol. 65, pp. 51–59, 2013.
[34] M. Erta, A. Quintana, and J. Hidalgo, “Interleukin-6, a major
cytokine in the central nervous system,” International Journal
of Biological Sciences, vol. 8, no. 9, pp. 1254–1266, 2012.
[35] S. L. Deshmane, S. Kremlev, S. Amini, and B. E. Sawaya, “Mono-
cyte chemoattractant protein-1 (MCP-1): an overview,” Journal
of Interferon and Cytokine Research, vol. 29, no. 6, pp. 313–326,
2009.
[36] J. Rojas, J. N. Domı´nguez, J. E. Charris, G. Lobo, M. Paya´, and
M. L. Ferra´ndiz, “Synthesis and inhibitory activity of dimethyl-
amino-chalcone derivatives on the induction of nitric oxide
synthase,” European Journal of Medicinal Chemistry, vol. 37, no.
8, pp. 699–705, 2002.
[37] H. Hara, Y. Nakamura, M. Ninomiya et al., “Inhibitory effects
of chalcone glycosides isolated from Brassica rapa L. ‘hidabeni’
and their synthetic derivatives on LPS-induced NO production
in microglia,” Bioorganic & Medicinal Chemistry, vol. 19, no. 18,
pp. 5559–5568, 2011.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
